TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient with a histologically proven cancer regardless of the location (solid tumor or not) except brain tumor~2. Patient should receive chemotherapy (any indication) associated with overall risk of neutropenia greater than or equal to 20%~3. Age ≥ 18 years~4. Performance Status ≤ 3~5. Patient with Internet access and an email box~6. Patient affiliated to a social security scheme~7. Patient has given its written consent before any specific procedure for the study~Exclusion Criteria:~1. Symptomatic brain metastases~2. Persons deprived of liberty, under guardianship or under curators~3. dementia, mental impairment or psychiatric illness that may affect the patient's informed consent and / or protocol adherence and monitoring of the test~4. Patient unable to submit the protocol followed for psychological, social, family or geographical reasons~5. Pregnant or breastfeeding~6. Patients at risk of severe neutropenia (Absolute Neutrophils Count \<0.1 Giga / L within 7 days prior to inclusion, acute leukemia, auto or allograft)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Monitoring by Web application (Type: EXPERIMENTAL): Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Delirium in the Elderly With Donepezil: a Double-blind, Randomized, Placebo-controlled Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Over 60 year old~* Delirium according to the CAM-ICU (Confusion Assessment Method for Intensive Care Unit)~* informed consent (legal representatives)~Exclusion Criteria:~* unable to swallow pills~* previous allergy to donepezil~* Atrioventricular block of 2nd and 3nd degree

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- donepezil (Type: EXPERIMENTAL): Donepezil 5mg/day during 2 weeks
- placebo (Type: PLACEBO_COMPARATOR): placebo comparator to donepezil (double blind)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intensive Case Diabetes Management (ICDM) to Prevent Readmission

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients admitted with a diagnosis of diabetes, Patients with a previous history of Pharmacy Expert System (PES) alert, Enrollment in research must be within 24 hours of admission~Exclusion Criteria:~* Patients transferred from institutionalized care, Patients who already plan to move to institutionalized care, Patients with severe co-morbidities (e.g. terminal cancer), Patients admitted for surgery within 24 hours, Patients who are unwilling or unable to give written consent (e.g. dementia), Patients who are homeless, Patients previously admitted to the diabetes endocrine service

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intensive Diabetes Case Management (Type: ACTIVE_COMPARATOR): Intensive Case Diabetes Management : A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE
- Control :Standard/ usual care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sternotomies and PectoIntercostal Fascia Blocks in Fast-Track Cardiac Anesthesiology

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients presenting to the Mazankowski Heart Institute for operations via full midline sternotomy, i.e.: coronary artery bypass grafting, and/or single valve repair or single valve replacement who are expected to be fast track candidates post-operatively.~* patients scheduled for cardiac bypass grafting and/or single valve surgery requiring cardiopulmonary bypass.~Exclusion Criteria:~* Unstable or fluctuating cardiac condition (acute MI, HF, tamponade, type A dissection, ongoing refractory arrhythmia, LVEF \<40%, massive transfusion protocol, reinstitution of CPB or other mechanical support)~* Alternative surgical approach (e.g. thoracotomy, mini sternotomy)~* Repeat sternotomy or emergency surgery~* Pregnancy or lactation~* Age \<18~* Chronic pain~* Tolerance to opioids~* Active alcohol misuse disorder, IVDU or cannabis use \>1g/d~* Allergy to local anesthetics~* Inability to provide informed consent~* High doses of steroids pre-operatively (\>10 mg prednisone/day)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): This group of patients will undergo placement of US guided pectointercostal fascia blocks.
- Placebo (Type: PLACEBO_COMPARATOR): The control group patients will receive the same intraoperative analgesia management. A PIF block will not be performed, instead, a peripheral nerve block catheter will be secured to the skin surface and connected to a CADD™ pump. As the catheter is taped to the skin surface the control group patients will not be exposed to the risks of peripheral nerve block placement.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Exercise and Education After Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of CAP or HCAP via radiographic imaging and symptoms of pneumonia Age 40 and above.~2. Discharge to home.~3. Ability to read and sign consent.~4. Ability to perform in procedures/exercise.~5. Ability to understand educational component of the program.~6. Antibiotic administration for pneumonia within 12 hours of admission.~Exclusion Criteria:~1. Severe lung diseases like ILD(Interstitial Lung disease), ARDS (Adult Respiratory Distress Syndrome.)~2. Ventilator dependent patients.~3. Discharge to nursing home.~4. Comorbidity that could limit exercise training.~5. Dementia, Schizophrenia or any active severe psychiatric disorder.~6. Any Active Malignancy or diagnosis of Lung malignancy.~7. Inability to attend program two times per week.~8. Recent myocardial infarction within two months.~9. Unstable angina, Heart failure (NYHA class III and IV.)~10. Patients with pneumonia who did not receive antibiotics within 12 hours of admission.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Interventional 40-60 (Type: ACTIVE_COMPARATOR): Interventional group aged 40-60
- Control 40-60 (Type: NO_INTERVENTION): Control group aged 40-60
- Interventional 60 and above (Type: ACTIVE_COMPARATOR): Interventional group aged 60 and above
- Control 60 and above (Type: NO_INTERVENTION): Control group aged 60 and above

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome.~* Performance status 0-2 (Zubrod scale).~* Serum creatinine equal or less than 1.3 mg/dL or creatinine clearance \> 40 mL/min.~* Bilirubin \</= 2 mg/dL; serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic pyruvic transaminase (SGPT) \</= 3 times the Upper Limit of Normal (ULN) for the reference lab unless due to leukemia or congenital hemolytic disorder (for bilirubin).~* Written informed consent.~Exclusion Criteria:~* No untreated or uncontrolled life-threatening infection.~* No oxaliplatin, fludarabine, or cytarabine intolerance.~* No pregnancy or lactation. Female patients of childbearing potential (including those \< 1 year post-menopausal) and male patients must agree to use contraception.~* No chemotherapy or radiation therapy within 4 weeks of study entry. Hydroxyurea is allowed prior to starting therapy in the setting of rapidly proliferating disease.~* No other medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent or cooperate and participate in the study or to interfere with the interpretation of the results.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxaliplatin + Cytarabine + Fludarabine (Type: EXPERIMENTAL): Oxaliplatin 30 mg/m\^2 intravenous (IV) days 1-4, Cytarabine 500 mg/m\^2 by IV continuous infusion days 2-6, Fludarabine 30 mg/m\^2 IV days 2-6

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed germ cell tumor (seminoma or non-seminoma) with measurable metastatic disease either by radiography (at a site which has previously not been irradiated) or elevation of alpha fetoprotein (AFP) and/or elevation of beta-human chorionic gonadotropin (beta-HCG);~* Patient previously treated with standard BEP (3 or 4 cycles) with relapse 1 months or more after favorable response on previous chemotherapy (CR or PR)~* Male~* Age greater than or equal to 18 years;~* Performance status 0,1,2 or 3~* WBC \> 3000 mill/l, ANC \> 1500 mill/l, platelet count \> 100.000 mill/l; serum bilirubin \< 1.5 x the upper limit of normal;~* Adequate renal function (Glomerular Filtration Rate (GFR) \>60 ml/min). GFR will be assessed by direct measurement (EDTA clearance or creatinine clearance)~* signed informed consent;~Exclusion Criteria:~* Uncontrolled active severe clinical infection (CTC grade 3 or 4).~* Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator), including expected difficulty of follow-up related to mental disorders.~* Grade 2 or greater peripheral neuropathy according to the CTC, version 3.0.~* Second malignancy other than basal or squamous cell skin cancer.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- GCT (Type: OTHER): cisplatin Paclitaxel gemcitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Role of the Premotor Cortex in Higher Cognitive Functions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects chosen from a pool of adult subjects, recruited through ads.~* In the second group, the subjects are recruited from a pool of brain-damaged patients treated at the hospital de la Pitié-Salpétrière. They must suffer from a focal lesion in the prefrontal cortex.~Exclusion Criteria:~* For the healthy group: any previous brain-related medical history.~* Widespread brain-damage, extending beyond the prefrontal cortex, that is to say, lesions that are not really focal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): The study compares brain-damaged patients with healthy ones on two psychophysical tasks.
- 2 (Type: None): The study does not intervene on the brain-damaged patients, it merely compares their behaviour with that of healthy patients on a range of psychophysical tasks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Preoperative Disinfection of Eyes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients remitted to intravitreal injections at St. Olavs hospital.~* Patients competent to give written consent~Exclusion Criteria:~* Infectious disease~* Known epitheliopathy~* Contact lens wear~* Use of prescription ophthalmic medications~* Diabetes

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Povidone-Iodine 0.3 % (Type: EXPERIMENTAL): A tampon is soaked in diluted PI 0.3% and placed on the inside of the lower eyelid of one eye, where it will release iodine molecules for 20 minutes before being removed.
- Povidone-Iodine 5 % (Type: ACTIVE_COMPARATOR): Eye drops of 5% PI is the standard disinfection before eye surgery. The drops will be dripped in one eye and allowed to work for 2 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. DSM-5 diagnosis of PTSD with duration \>6 months, as confirmed by psychiatric evaluation.~2. CAPS-5 total score ≥30 at Screening and Baseline.~3. Body mass index (BMI) of 18 to 38 kg/m2.~Exclusion Criteria:~1. Experienced the index traumatic event before age 16.~2. Has an active legal, worker's compensation, or disability claim for PTSD.~3. Lifetime history of bipolar disorder, a psychotic disorder (eg, schizophrenia or schizoaffective disorder), or obsessive-compulsive disorder or a history of a psychotic mood episode in last 2 years.~4. HAM-D17 score of \>18 at Screening or Baseline.~5. Any current psychiatric disorder (other than PTSD).~6. Lifetime history of seizures, including febrile seizures.~7. Daily consumption of more than 2 standard alcohol-containing beverages for males or more than 1 standard alcohol-containing beverages for females.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Double-blind PRAX-114 (Type: EXPERIMENTAL): Double-blind period - 40 or 60 mg PRAX-114 once daily in the evening
- Double-blind Placebo (Type: PLACEBO_COMPARATOR): Double-blind period - placebo once daily in the evening
- Open-label Extension PRAX-114 (Type: EXPERIMENTAL): Open-label extension period - 40 mg PRAX-114 once daily in the evening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Statin Use in Patients With Acute VTE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old~* A diagnosis of proximal DVT (proximal to and including popliteal vein), with or without PE, confirmed by objective imaging studies, such as Doppler ultrasound, venograms (for DVT) and/or computer tomography, angiograms, ventilation-perfusion scan (for PE)~* Treated with warfarin as anticoagulation (short-term bridging with heparin or lovenox is allowed)~Exclusion Criteria:~* Thrombolysis within 6 weeks prior to enrollment~* Patients with statin use within 6 weeks of enrollment~* Patients with known allergy or intolerance to statins or statins are contraindicated for any other reasons~* Patients with baseline aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin ≥2.0 x upper limit of normal (ULN)~* Pregnant or breastfeeding females are excluded~* Any malignancy diagnosed within the preceding 2 years, except for squamous cell carcinoma or basal cell carcinoma of skin treated with local resection only, or carcinoma in situ of the cervix~* Incarcerated patients are excluded from the study due to the inherent difficulties in maintaining close follow-up for study purposes in patients who are incarcerated.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anticoagulation (Type: ACTIVE_COMPARATOR): Patients will be treated with warfarin with dose adjusted to goal International Normalized Ratio (INR) of 2-3 or rivaroxaban standard dose (15 mg twice daily for 3 weeks then 20 mg daily)
- Atorvastatin + anticoagulation (Type: EXPERIMENTAL): In addition to standard anticoagulation, patients will be given concurrent atorvastatin 40 mg daily for the study period of 9 months, starting from the time of enrollment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Online Mindfulness for Medical Trainees

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~- A medical trainee who registered for the online mindfulness elective~Exclusion Criteria:~- None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Pre-clerkship cohort (Type: EXPERIMENTAL): First- and second-year medical students
- Clerkship cohort (Type: EXPERIMENTAL): Third- and fourth-year medical students
- Resident cohort (Type: EXPERIMENTAL): Medical residents

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Determination of the Efficacy and Safety of Psoralait Versus Placebo in the Treatment of Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have been clinically diagnosed as suffering from psoriasis and are or aren't scheduled for Narrow Band Ultraviolet B (UVB)phototherapy of affected areas,excluding face and genitalia.~Exclusion Criteria:~* Women who are pregnant, lactating, planning to become pregnant, or women of child-bearing potential who have not successfully been using the same medically acceptable contraceptive methods over the previous 3 months, e.g., oral contraceptive agents, intrauterine device (IUD) and barrier method plus spermicide.~* Use of topical anti psoriatic therapy (including topical retinoids, corticosteroids, or vitamin D analogs) on the areas to be treated within 2 weeks prior to the beginning of the study.~* Received systemic biologic therapy to treat psoriasis (for example: alefacept, etanercept, infliximab, adalimumab) within 12 weeks prior to the beginning of the study.~* Received systemic psoriasis therapy (for example: methotrexate, cyclosporine, systemic corticosteroids, retinoids such as acitretin) within 4 weeks prior to the beginning of the study.~* Received phototherapy (including laser), photo chemotherapy or climatotherapy within 4 weeks prior to the beginning of the study.~* Recent history (within past 12 months) of alcohol or substance abuse. Alcohol abuse will be defined as \>14 drinks per week (1 drink = 12 oz beer, 4 oz wine, or 1.5 oz distilled spirits).~* History of noncompliance to medical regimens or unwilling to comply with the study protocol.~* Participation in an investigational drug study within 30 days prior to the beginning of the study.~* Serious or unstable medical or psychological conditions that in the opinion of the Investigator would compromise the subject's safety or successful participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Psoralait (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues